Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV147 in Healthy Participants
NCT07885202Phase 1Not yet recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Oct 2026
- Primary completion
- May 2027
01
Overview
Phase 1, randomised, double-blind trial of VV147 (7 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum Plasma Concentration at 168 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 168 hours and 11 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VV147
Beyond the preview
Go deeper on NCT07885202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885202.